Galectin-3C combination therapy for human cancer

• US 9,272,014 B2
• Filed: 03/29/2012
• Issued: 03/01/2016
• Est. Priority Date: 03/29/2011
• Status: Active Grant

• Current Assignee: MandalMed, Inc., Texas Tech University System
• Original Assignee: MandalMed, Inc., Texas Tech University System
• Inventors: Chiriva-Internati, Maurizio, Cobos, Everardo, John, Constance
• Primary Examiner(s): Cordero Garcia, Marcela M
• Application Number:
  US14/008,262
• Publication Number:
  US 20140243275A1
• Time in Patent Office: 1,433 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 38/05 Dipeptides
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 38/1732 Lectins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

Claims

1. A pharmaceutical combination having therapeutic synergy comprising:

an effective amount of galectin-3C and the proteasome inhibitor bortezomib.

2. The pharmaceutical combination of claim 1, wherein the galectin-3C and the proteasome inhibitor are administered separately.

3. The pharmaceutical combination of claim 1, wherein the galectin-3C and the proteasome inhibitor bortezomib are administered immediately or by extended release.

4. A pharmaceutical combination having therapeutic synergy comprising

an effective amount of galectin-3C and bortezomib to overcome resistance to bortezomib, wherein the galectin-3C and bortezomib are administered separately or simultaneously.

5. The pharmaceutical combination of claim 4, wherein the composition is useful in treating cancer in vivo.

6. The pharmaceutical combination of claim 5, wherein the cancer is multiple myeloma.

7. A pharmaceutical combination having therapeutic synergy comprising an effective amount of galectin-3C and salinosporamide A or carfilzomib.

8. The pharmaceutical combination of claim 7, wherein said combination is useful in treating cancer in vivo, wherein said cancer is multiple myeloma.

11. The pharmaceutical combination of claim 7, wherein the galectin-3C, and the salinosporamide A or the carfilzomib, are administered separately.

9. A pharmaceutical combination comprising an effective amount of galectin-3C and proteasome inhibitor bortezomib to synergistically inhibit angiogenesis.

12. The pharmaceutical combination of claim 9, wherein the combination of galectin-3C and proteasome inhibitor bortezomib is useful in treating cancer in vivo.

13. The pharmaceutical combination of claim 9, wherein the combination of galectin-3C and proteasome inhibitor bortezomib is useful in treating multiple myeloma in vivo.

10. A pharmaceutical combination comprising an effective amount of galectin-3C and a proteasome inhibitor that synergistically inhibit angiogenesis.